Chennai Meenakshi Multispeciality Hospital Ltd vs Thyrocare Technologies Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: Oct 31, 2026

Key Highlights

The Latest Trading Price of Chennai Meenakshi Multispeciality Hospital Ltd is ₹ 33.15 as of 30 Oct 15:30 . The P/E Ratio of Chennai Meenakshi Multispeciality Hospital Ltd changed from 0 on March 2021 to 0 on March 2026 . This represents a CAGR of 0.0% over 6 yearsThe P/E Ratio of Thyrocare Technologies Ltd changed from 42.2 on March 2021 to 34.2 on March 2026 . This represents a CAGR of -3.44% over 6 years The Market Cap of Chennai Meenakshi Multispeciality Hospital Ltd changed from ₹ 0 crore on March 2021 to ₹ 0 crore on March 2026 . This represents a CAGR of 0.0% over 6 yearsThe Market Cap of Thyrocare Technologies Ltd changed from ₹ 4774 crore on March 2021 to ₹ 5566 crore on March 2026 . This represents a CAGR of 2.59% over 6 years The revenue of Chennai Meenakshi Multispeciality Hospital Ltd for the Sep '26 is ₹ 0 crore as compare to the Jun '26 revenue of ₹ 0 crore. This represent the decline of 0% The revenue of Thyrocare Technologies Ltd for the Sep '26 is ₹ 275.24 crore as compare to the Jun '26 revenue of ₹ 244.88 crore. This represent the growth of 12.4% The ebitda of Chennai Meenakshi Multispeciality Hospital Ltd for the Sep '26 is ₹ 0 crore as compare to the Jun '26 ebitda of ₹ 0 crore. This represent the decline of 0% The ebitda of Thyrocare Technologies Ltd for the Sep '26 is ₹ 48.74 crore as compare to the Jun '26 ebitda of ₹ 82.13 crore. This represent the decline of -40.66% The net profit of Chennai Meenakshi Multispeciality Hospital Ltd changed from ₹ 0 crore to ₹ 0 crore over 10 quarters. This represents a CAGR of 0.0% The net profit of Thyrocare Technologies Ltd changed from ₹ 23.94 crore to ₹ 15.22 crore over 10 quarters. This represents a CAGR of -16.57% The Dividend Payout of Chennai Meenakshi Multispeciality Hospital Ltd changed from 0 % on March 2021 to 0 % on March 2026 . This represents a CAGR of 0.0% over 6 yearsThe Dividend Payout of Thyrocare Technologies Ltd changed from 110.36 % on March 2021 to 149.75 % on March 2026 . This represents a CAGR of 5.22% over 6 years .

About Chennai Meenakshi Multispeciality Hospital Ltd

Chennai Meenakshi Multispeciality Hospital Limited, formerly known as Devaki Hospital Limited, was incorporated in 1990.
The Company name was changed from Devaki Hospital Limited to Chennai Meenakshi Multispeciality Hospital Limited in October, 2007.
It is a 100-bedded hospital located in the heart of Chennai at Mylapore.
The hospital has an infrastructure comprising of around 105 Beds including ICU Beds, Operating Theatre, a modern dialysis Unit besides a host of other facilities.
The Company has a pool of talented and experienced doctors who are further supported by a team of highly qualified and experienced and dedicated support staff and cutting edge technology. The Company operate into various departments like Cardiology Department; Casualty Department; Diagnostic Services; Intensive Care Unit; Nephrology Department and Physiotherapy Department.

About Thyrocare Technologies Ltd

Thyrocare Technologies Limited was incorporated in January, 2000.
The Company operates in the healthcare industry and is involved in providing quality diagnostic services at affordable costs to patients, laboratories and hospitals in India. As of 31 March 2025, the Company offered more than 920 distinct tests that support early detection, preventive care and the ongoing disease monitoring.
Their 43 profiles are administered under its reputed 'Aarogyam' brand, which offers patients a suite of wellness and preventive health care tests.
The Company primarily operates its testing services through a fully automated Centralised Processing Laboratory (the CPL) and has expanded its operations to include a network of Regional Processing Laboratories (RPLs).
The company currently operates 25 RPLs, one in each of New Delhi, Coimbatore, Hyderabad, Kolkata, Bangalore, Bhopal, Mumbai Patna and Chennai, which process samples sourced from their respective regions.

FAQs for the comparison of Chennai Meenakshi Multispeciality Hospital Ltd and Thyrocare Technologies Ltd

Which company has a larger market capitalization, Chennai Meenakshi Multispeciality Hospital Ltd or Thyrocare Technologies Ltd?

Market cap of Chennai Meenakshi Multispeciality Hospital Ltd is 24 Cr while Market cap of Thyrocare Technologies Ltd is 7,273 Cr

What are the key factors driving the stock performance of Chennai Meenakshi Multispeciality Hospital Ltd and Thyrocare Technologies Ltd?

The stock performance of Chennai Meenakshi Multispeciality Hospital Ltd and Thyrocare Technologies Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Chennai Meenakshi Multispeciality Hospital Ltd and Thyrocare Technologies Ltd?

As of October 31, 2026, the Chennai Meenakshi Multispeciality Hospital Ltd stock price is INR ₹33.15. On the other hand, Thyrocare Technologies Ltd stock price is INR ₹457.0.

How do dividend payouts of Chennai Meenakshi Multispeciality Hospital Ltd and Thyrocare Technologies Ltd compare?

To compare the dividend payouts of Chennai Meenakshi Multispeciality Hospital Ltd and Thyrocare Technologies Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.